* Integra Lifesciences Holdings Corp IART.OQ reported
quarterly
adjusted earnings of 41 cents per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of 76 cents. The mean expectation of
thirteen analysts for the quarter was for earnings of 39 cents
per share. Wall Street expected results to range from 35 cents
to 42 cents per share.
* Revenue fell 0.9% to $380.83 million from a year ago;
analysts
expected $375.78 million.
* Integra Lifesciences Holdings Corp's reported EPS for the
quarter was a loss of 14 cents.
* The company reported a quarterly loss of $10.7 million.
* Integra Lifesciences Holdings Corp shares had risen
by 6.1% this
quarter and lost 55.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 7
"hold" and 4 "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "hold"
Wall Street's median 12-month price target for Integra
Lifesciences Holdings Corp is $25.00
This summary was machine generated from LSEG data November 4 at
03:28 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.39 0.41 Beat
Jun. 30 2024 0.62 0.63 Beat
Mar. 31 2024 0.55 0.55 Met
Dec. 31 2023 0.90 0.89 Missed